Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).
Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results